Article

Kemin launches lutein campaign

Kemin has launched a national marketing campaign to promote its brand of lutein (FloraGLO) and educate consumers about the role lutein plays in maintaining healthy vision.

Des Moines, IA-Kemin has launched a national marketing campaign to promote its brand of lutein (FloraGLO) and educate consumers about the role lutein plays in maintaining healthy vision.

“Nearly half of the U.S. population has low levels of lutein in their eyes, putting them at risk for developing certain eye conditions as they age,” said Linda Fullmer, senior vice president of Kemin. “Too many people are still unaware that there are easy steps, like taking a daily eye vitamin, that can protect, prolong, and improve their visual performance.”

Research indicates that people need 10 mg of lutein every day through diet and eye vitamins, according to the company, and most Americans are getting no more than 2 mg daily through their diets.

The marketing campaign will leverage alliances with the American Optometric Association, Prevent Blindness America, and AMD Alliance International, and will include national programs, doctor education, and consumer outreach. Involved in the campaign will be visually impaired national and world triathlon champion Aaron Scheidies; model Emme; track and field athlete Lolo Jones; and nutritionist and fitness expert Jennifer Galardi.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.